미국 · 보도자료 · Lisata Therapeutics, Inc. · 2026-10-05 12:00
말단비대증 치료제 후보물질 MAR002, 임상 2상 첫 환자 투약
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care
